Research Reports

Key takeaways

Apyx Medical received expanded 510(k) clearance from U.S. FDA for AYON Body Contouring System on May 11, 2026.

Clearance adds power liposuction using reciprocating cannula to enhance fat removal efficiency and reduce surgeon effort and OR time.

Company plans limited commercial launch of power liposuction function to refine training and customer experience before scaling.

AYON now integrates fat removal, closed loop contouring, Renuvion tissue contraction, and electrosurgical capabilities in one platform.

Addition of power liposuction expected to drive greater market demand for AYON.

Full analysis

Apyx Medical Corporation announced expanded 510(k) clearance for its AYON Body Contouring System, adding power liposuction as a second advanced liposuction modality. This enhancement uses a reciprocating cannula to improve efficiency in fat removal, reducing surgeon effort and operating room time. CEO Charlie Goodwin stated that AYON is now the gold-standard system in surgical aesthetics, enabling multiple body contouring modalities in a unified platform to streamline workflows and support patient outcomes. The company filed for this label expansion in October 2025 and plans a limited commercial launch to work with early adopters on training and utilization before broader rollout, positioning AYON to capture increased market demand in the surgical aesthetics sector.

APYX · Apyx Medical Corporation

Summary

Key takeaways

Full analysis